{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "PRE", "regularMarketPrice": 0.3043, "exchangeTimezoneShortName": "EDT", "exchangeTimezoneName": "America/New_York", "currency": "USD", "market": "us_market", "esgPopulated": false, "messageBoardId": "finmb_546709785", "gmtOffSetMilliseconds": -14400000, "shortName": "TransCode Therapeutics, Inc.", "longName": "TransCode Therapeutics, Inc.", "regularMarketChangePercent": 0.7615974, "exchange": "NCM", "regularMarketChange": 0.002300024, "regularMarketTime": 1684179861, "regularMarketDayHigh": 0.3062, "regularMarketDayRange": "0.29 - 0.3062", "regularMarketDayLow": 0.29, "regularMarketVolume": 35439, "regularMarketPreviousClose": 0.302, "bid": 0.0, "ask": 0.0, "bidSize": 32, "askSize": 11, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.29, "averageDailyVolume3Month": 882435, "averageDailyVolume10Day": 178190, "fiftyTwoWeekLowChange": 0.023300022, "ipoExpectedDate": "2021-07-09", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "fiftyTwoWeekLowChangePercent": 0.082918234, "fiftyTwoWeekRange": "0.281 - 2.225", "fiftyTwoWeekHighChange": -1.9206998, "fiftyTwoWeekHighChangePercent": -0.8632359, "fiftyTwoWeekLow": 0.281, "fiftyTwoWeekHigh": 2.225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.4, "epsForward": -0.79, "epsCurrentYear": -0.87, "priceEpsCurrentYear": -0.34977013, "sharesOutstanding": 15823500, "bookValue": 0.25, "fiftyDayAverage": 0.35214, "fiftyDayAverageChange": -0.04784, "fiftyDayAverageChangePercent": -0.13585505, "twoHundredDayAverage": 0.70775, "twoHundredDayAverageChange": -0.40345, "twoHundredDayAverageChangePercent": -0.57004595, "marketCap": 4815091, "forwardPE": -0.38518986, "priceToBook": 1.2172, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "firstTradeDateMilliseconds": 1625751000000, "priceHint": 4, "displayName": "TransCode Therapeutics", "symbol": "RNAZ"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "6 Liberty Square", "address2": "Suite 2382", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "857-837-3099", "website": "https://www.transcodetherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert Michael Dudley", "age": 71, "title": "Co-Founder, CEO, Pres & Director", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": {"raw": 494000, "fmt": "494k", "longFmt": "494,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 477391, "fmt": "477.39k", "longFmt": "477,391"}}, {"maxAge": 1, "name": "Mr. Thomas A. Fitzgerald M.B.A.", "age": 70, "title": "CFO, VP of Admin. & Director", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": {"raw": 371000, "fmt": "371k", "longFmt": "371,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 143875, "fmt": "143.88k", "longFmt": "143,875"}}, {"maxAge": 1, "name": "Dr. Zdravka  Medarova Ph.D.", "age": 47, "title": "Co-Founder, CTO & Member of Advisory Board", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Anna  Moore Ph.D.", "age": 60, "title": "Co-Founder, Scientific Advisor & Member of Scientific Advisory Board", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Susan  Duggan M.B.A., R.N.", "title": "Sr. VP of Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Qiyong Peter Liu Ph.D.", "age": 58, "title": "VP of Drug Discovery & Chief Scientist", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alan  Freidman", "title": "VP of Investor & Client Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}